政府新闻
默克扩建位于上海的生物安全检测实验中心 2023-11-23
German pharmaceutical giant Merck Group has put into operation the second phase of its biosafety test and experiment center in Shanghai.
The project's latest phase can provide a wide range of biosafety testing services for monoclonal antibodies, other recombinant proteins, and cell and gene therapies, meeting the requirements for the mass prod uction of biologics in preclinical and clinical studies and approved biologics, Merck said yesterday.
The first stage, completed and put into operation in September last year, mainly provides virus clearance validation services. The two phases have a total investment of EUR29 million (USD31.7 million) and mainly provide testing services for Chinese biopharmaceutical firms and contract developers and manufacturers.
Merck’s Shanghai center will become a key part of its global biosafety testing service network, Dirk Lange, head of life science services at the company’s Life Science business, said at yesterday’s inauguration ceremony.
It can provide China's biopharma industry with services that meet global standards and can help Chinese firms speed up drug approvals in overseas markets, according to industry insiders.
The global biosafety testing market may reach USD5 billion by 2025 and expand to USD10 billion by 2030, based on industry data. The Chinese market is worth about USD100 million, with double-digit annual growth, much faster than the worldwide average.
Merck has built biosafety testing centers in Singapore, Stirling and Glasgow in the United Kingdomw and Rockville and Maryland in the United States. They share the same global expertise, standards, and operation systems.
But Merck's testing center in Shanghai needs to compete with domestic test centers. WuXi Advanced Therapies, a contract tester, developer, and manufacturer owned by WuXi AppTec, specializes in cell and gene therapies and provides industrial testing services for development, biosafety, viral clearance, and final drug release.
Source: Yicai Global
